Arsenic trioxide is a chemotherapeutic agent of idiopathic function used to treat leukemia that is unresponsive to first line agents. It is suspected that arsenic trisulfide induces cancer cells to undergo apoptosis. In general, arsenic is known to be a naturally toxic substance capable of eliciting a variety of dangerous adverse effects. The enzyme thioredoxin reductase has recently been identified as a target for arsenic trioxide.
Science-backed PDE/ADE, OEL & OEB derivation by certified toxicologists with ex-agency experts -
Arsenic Trioxide
Drug Overview
What is Arsenic Trioxide?
To derive PDE/ADE, OEL, and OEB values, Masuu Global follows a scientifically justified, risk-based toxicological assessment approach in accordance with internationally recognized guidelines and industry best practices that are widely accepted by regulatory authorities, including European Medicines Agency (EMA), Pharmaceutical Inspection Co-operation Scheme (PIC/S), and Agência Nacional de Vigilância Sanitária (ANVISA).
Request Your Assessment
Add this compound to your inquiry list and our team will follow up with full documentation, pricing, and licensing terms.
View Inquiry List →Full OEL derivation · ADE/PDE value · Control band assignment · All cited references · EMA / ICH Q9 compliance
Regulatory Framework
Assessment Methodology
Masuu Global follows a scientifically justified, risk-based toxicological approach aligned with internationally recognized guidelines accepted by EMA, PIC/S, and ANVISA.
EMA – Guideline on Setting Health-Based Exposure Limits (HBELs)
Provides the framework for establishing scientifically justified PDE/ADE values for use in shared manufacturing facilities.
PIC/S – Shared Facilities and Contamination Control Guidance
Supports the application of HBEL-based approaches for cross-contamination prevention and cleaning validation.
ICH Q9 – Quality Risk Management
Provides a structured methodology for risk identification, assessment, control, communication, and review.
ICH M7 – Assessment and Control of DNA-Reactive (Mutagenic) Impurities (where applicable)
Applied for compounds with potential mutagenic or genotoxic concerns.
Risk-Based Toxicological Assessment
Comprehensive evaluation of available toxicological and pharmacological data, including NOAEL, LOAEL, BMDL, pharmacological potency, carcinogenicity, reproductive and developmental toxicity, sensitization potential, and target organ toxicity.
Weight-of-Evidence (WoE) Approach
Integration and critical review of all relevant data sources, including non-clinical studies, clinical studies, human exposure data, pharmacological information, post-marketing safety data, and structure–activity relationship (SAR/QSAR) assessments.
How We Work
Report Preparation Process
Every assessment moves through a rigorous five-stage workflow — from data gathering to regulatory-ready delivery.
Comprehensive Data Review
Assessment of pharmacology, toxicology, clinical data, literature, and available regulatory information.
Scientific Evaluation
Identification of critical endpoints and selection of appropriate exposure limits.
PDE / HBEL Derivation
Transparent and scientifically justified calculations aligned with global toxicological principles.
Ex-Agency Expert Review (Our Differentiator)
Reports are reviewed with an ex-agency perspective, bringing regulatory expectations, inspection readiness, and practical implementation into every assessment.
Final Report Delivery
Regulatory-ready reports with scientific rationale, calculations, and clear recommendations by certified toxicologists (ERT, UKRT and DABT).
Ex-Agency Advantage
Why Masuu Global?
Our ex-agency toxicologists bring a practical regulatory perspective that transforms how assessments are built, reviewed, and defended.
Regulatory expectation–driven assessments aligned with how authorities actually evaluate submissions.
Inspection-ready reports — scientifically defensible and audit-prepared from day one.
Faster review cycles with direct decision support from certified toxicologists (ERT, UKRT, DABT).
Practical implementation recommendations that translate science into actionable contamination control.
Reduced internal effort — offload complex assessments without sacrificing quality or defensibility.
Global reach across PDE/ADE, HBEL, OEL, OEB, cleaning validation, and impurity assessments.
Ready to request your assessment?
Add this compound to your inquiry list, or browse our full database of 3,000+ molecules.
Frequently Asked Questions
Arsenic Trioxide is an inorganic arsenic compound used as an anticancer medicine, particularly for acute promyelocytic leukaemia. Inorganic arsenic compounds are recognised as highly toxic and carcinogenic in humans. A careful toxicological assessment is therefore essential for setting health-based limits, containment and cross-contamination control during manufacturing.
A PDE or ADE sets a health-based limit on daily exposure to Arsenic Trioxide from residual carryover. Manufacturers use it in cross-contamination risk assessments and cleaning validation when the compound is processed in shared equipment or facilities. Whether a report is required depends on how it is used and on applicable regulatory expectations.
Carryover is evaluated by comparing the amount of Arsenic Trioxide that could remain on shared equipment after cleaning with the PDE. The maximum daily dose of the next product and the shared equipment surface area are typically considered. This approach helps manufacturers set justified cleaning limits and decide whether dedicated equipment or additional controls are needed.
An assessment should be reviewed when new toxicological or clinical data become available, when the way the substance is used or handled changes, or when relevant regulatory guidance is updated. Periodic review keeps the limits for Arsenic Trioxide aligned with current evidence and helps ensure that containment and cleaning decisions remain scientifically justified.
Yes. Clinical information, such as the lowest therapeutic dose and adverse effects observed in patients, can provide a useful point of departure when it is relevant and well documented. For Arsenic Trioxide, such data are weighed against non-clinical findings, and appropriate adjustment factors are applied so that the resulting limits protect both patients and workers.
An OEL is derived by reviewing the toxicological and occupational health evidence, identifying the critical effect, and applying a recognized assessment methodology. The final value should come with a documented rationale, clearly stated units, and the exposure duration it applies to, so it can be used confidently in workplace risk assessment.
An OEB places Arsenic Trioxide in a hazard category using a defined banding framework and the available toxicological evidence. Criteria and numerical ranges differ between frameworks, so the report should identify the system used. The band then guides the level of containment and handling controls suited to the compound.
A Masuu Global report for Arsenic Trioxide presents the scientific rationale, the calculations behind each health-based limit and clear recommendations for its use. Reports are prepared by certified toxicologists following a risk-based approach and are designed to be regulatory-ready, so they can support cross-contamination risk assessments, cleaning validation and occupational safety programmes.
Yes. The physical form influences how easily Arsenic Trioxide can become airborne or come into contact with the skin. Fine powders generally present a greater inhalation risk than solutions or granulated materials, while volatile liquids may produce vapour. The assessment considers the forms handled at each stage so that containment and protective measures match the actual exposure potential.
Not always. An OEB places Arsenic Trioxide in a hazard band and is especially useful early in development or when data are limited. A specific OEL, where one can be derived, gives a more precise benchmark for exposure monitoring. Many organizations use the band to guide containment and the OEL to verify that controls are working as intended.
Masuu Global follows a scientifically justified, risk-based approach aligned with internationally recognized guidance accepted by regulators, including the EMA guideline on health-based exposure limits, PIC/S guidance on shared facilities and contamination control, ICH Q9 quality risk management, and ICH M7 where applicable.
Use the Request Your Assessment option on this page and add Arsenic Trioxide to your inquiry list. The Masuu Global team will follow up with full documentation, pricing, and licensing terms. Mention your intended use and market so the scope of the report can be confirmed.
